PMV Pharma reports 46% ORR in ovarian cancer cohort; NDA submission planned Q1 2027

PMV Pharmaceuticals, Inc.

ORR of 46% (35/76) in ovarian cancer cohort; median duration of response 10.0 months, median time to response 1.3 months.
FDA feedback supports NDA for accelerated approval; submission planned Q1 2027.
Enrollment for primary analysis in platinum-resistant/refractory ovarian cancer completed.
Safety: mostly Grade 1/2 AEs, 5% discontinuation due to treatment-related AEs.
Company to present update on all PYNNACLE cohorts at medical conference Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.